Furthermore, upregulation of PRPF8 correlates with poor prognosis in clinical liver cancer patients, acting as a tumor promoter by regulating the PI3K/Akt pathway in hepatic stellate cells and HCC cells, thereby enhancing liver cancer cell viability and metastatic potential. This evidence concerns the gene PRPF8 and liver cancer.